Member Info for CHELSEA7

Jinksy, tee hee

Kaneonaim, so how busy is the secret WhatsApp group, phone a friend line this morning.

Scooby was trained by Yoda and Multibagger BTW. Next placing no more than £250k at .35p, and Directors will be forced to buy shares, again. Going for a four timer.

My word you guys sunk low yesterday, most of your posts, if not all removed, and still throwing hissy fits at all those who have called this share correctly.

Amazes me, that with so many who have been right you still abuse us, and still claiming we are all filtered, so you are more than happy not to read the facts you go to enormous lengths to disguise.

Scooby, my old adversary, it would be nice if my infrequent posts were not immediately followed by your nasty digs, but hey, best for others to see the real you. Have a good day.

Yep, it has been a flying start to 2019 for IO deals and another boost for BioNTechs cash reserves. Here we see the investors behind BioNTech.................................

https://www.crunchbase.com/organization/biontech-ag#section-investors

Anyone of which would be so welcome here, yesterdays news..I found very interesting...................

.......BioNTech and Sanofi are yet to generate clinical data showing their assets can live up to that billing and deliver strong, highly targeted attacks on tumors. But news that the pair are working on a solid tumor trial of their lead program shows the first clinical evidence is now on the horizon., wondering more than ever how Moditope fits with BioNTech, in terms of potential deals, initially to ensure we have the funding for MOD1 trial in 2019

With the funding in place for SCIB1/2 combo trials (wish the patients were), Ivy mentioning after the AGM the BOD spoke of seeking non dilutive funding in their recent trip to China(presuming everybody was) our first commercial deal has never been more needed, and i wanted to ask anybody what their idea of the best deal for us is/ the type of deal the BOD will be striving for/ and how realistic either might be this coming year. CH himself has said on three occasions he has high hopes of more fruit coming our way from BioNTech............more fruit??

Any ideas, thoughts, from you guys, ........it is more than conceivable we could have three trials running during 2019, SCIB 1, SCIB 2, MOD 1, cannot see that driving a stagnant SP as has been suggested here

BioNTech and Sanofi are yet to generate clinical data showing their assets can live up to that billing and deliver strong, highly targeted attacks on tumors. But news that the pair are working on a solid tumor trial of their lead program shows the first clinical evidence is now on the horizon.

Nor should we forget todays Sanofi/Biontech deal...............................

RE: Sanofi/BioNTech DealToday 16:44Interesting stuff..........................

Sanofi is set to invest €80 million ($91 million) in BioNTech and extend its cancer collaboration with the German mRNA specialist. The agreement comes as BioNTech and Sanofi prepare to start clinical development of the first cancer immunotherapy to emerge from their 2015 pact.

France’s Sanofi began working with BioNTech late in 2015 when it paid $60 million upfront for the rights to five discovery-stage immunotherapies. As the immunotherapies advance, Sanofi will pay up to $300 million in milestones per asset, making the deal a potentially significant piece of business for both companies.

With that deal now bearing fruit, Sanofi has tightened its ties to BioNTech by agreeing to invest €80 million in its partner. The investment comes a year after BioNTech raised $270 million and five months after Pfizer bought a stake in the biotech as part of a deal worth $120 million in upfront and near-term payments.

BioNTech has secured the additional funding at a time when it is advancing on multiple fronts. Most recently, the biotech has exercised its option to co-develop one of the immunotherapies covered by the Sanofi agreement.

The co-developed asset, the most advanced of the drugs in the Sanofi pact, is made up a mixture of mRNAs that encode for immunomodulatory cytokines. When injected into tumors, synthetic mRNAs can induce the production of immunomodulatory molecules that induce immunity to tumor-specific antigens. Sanofi and BioNTech think the approach avoids the anti-vector immunity and expression in distant tissue that can affect viral gene therapies and oncolytic viruses.

BioNTech and Sanofi are yet to generate clinical data showing their assets can live up to that billing and deliver strong, highly targeted attacks on tumors. But news that the pair are working on a solid tumor trial of their lead program shows the first clinical evidence is now on the horizon.

The lead program has gone from concept to clinical development in less than three years, giving Sanofi and BioNTech a boost as they seek to carve out spaces in their respective fields. Sanofi has lagged behind its rivals in the oncology space, while BioNTech is scrapping with companies such as Moderna and CureVac for dollars and deals in the nascent mRNA sector

Good posts guys, goodnight

Buys 80k

Sells 112k

Interesting stuff..........................

Sanofi is set to invest €80 million ($91 million) in BioNTech and extend its cancer collaboration with the German mRNA specialist. The agreement comes as BioNTech and Sanofi prepare to start clinical development of the first cancer immunotherapy to emerge from their 2015 pact.

France’s Sanofi began working with BioNTech late in 2015 when it paid $60 million upfront for the rights to five discovery-stage immunotherapies. As the immunotherapies advance, Sanofi will pay up to $300 million in milestones per asset, making the deal a potentially significant piece of business for both companies.

With that deal now bearing fruit, Sanofi has tightened its ties to BioNTech by agreeing to invest €80 million in its partner. The investment comes a year after BioNTech raised $270 million and five months after Pfizer bought a stake in the biotech as part of a deal worth $120 million in upfront and near-term payments.

BioNTech has secured the additional funding at a time when it is advancing on multiple fronts. Most recently, the biotech has exercised its option to co-develop one of the immunotherapies covered by the Sanofi agreement.

The co-developed asset, the most advanced of the drugs in the Sanofi pact, is made up a mixture of mRNAs that encode for immunomodulatory cytokines. When injected into tumors, synthetic mRNAs can induce the production of immunomodulatory molecules that induce immunity to tumor-specific antigens. Sanofi and BioNTech think the approach avoids the anti-vector immunity and expression in distant tissue that can affect viral gene therapies and oncolytic viruses.

BioNTech and Sanofi are yet to generate clinical data showing their assets can live up to that billing and deliver strong, highly targeted attacks on tumors. But news that the pair are working on a solid tumor trial of their lead program shows the first clinical evidence is now on the horizon.

The lead program has gone from concept to clinical development in less than three years, giving Sanofi and BioNTech a boost as they seek to carve out spaces in their respective fields. Sanofi has lagged behind its rivals in the oncology space, while BioNTech is scrapping with companies such as Moderna and CureVac for dollars and deals in the nascent mRNA sector

https://www.fiercebiotech.com/biotech/sanofi-invests-eu80m-biontech-as-cancer-mrna-hits-clinic?mkt_tok=eyJpIjoiTVdJME1tUXlNRGczTkRSbSIsInQiOiJvMmV6UkNUalBiTmk2bWRNYzBQeGxvZVlBMVVkU2d2QmxcL0E3NzlkTVVwRGtmdTFPOXFuTzBadlRGQ2p5dGV1bXdrMWdLek5GRUQ1S3g4QmJUZWpCOXZTZVc4RG9hWDBuc3MrQ29mSFRmakZQeDJpRFNVaUlBWVwvMmJJNGVnczhiIn0%3D&mrkid=36433381&utm_medium=nl&utm_source=internal

Crumbs 14.49. many thanks.

Thanks Ray, ..............................a repost for all.

crumbs
Posts: 12,666
Opinion: No Opinion
Price: 8.625
2019Sun 10:24January- A win on the Grand Challenge-great pr and free IP enhancing development funding and a paid for proof of concept trial in head and neck cancer, pancreatic cancer, lung cancer and one type of brain tumour.Working with some of the biggest names in the field.

February- BioNtech announce they need moditope for their TCR program... a deal is done, a market surprising upfront payment of £30 million (as much as current mcap) with milestone payments etc and a trial pencilled in to begin H2
2019... all none IP diluting and paid for by BioNtech... AIM does not know how to react

March- FDA approval SCIB1 combo trial gets the green light... yeeeeha and pheww...

April- Modi1 trial begins

May- SCIB1 combo trial begins in US ran by the best in the best clinics.

June- CRUK is manufacturing SCIB2 we get to know more about nanovesicle delivery all costs covered by CRUK trial expected to commence H2

July-Scancell announce they will take forward into trial a new SCIB with Van Geest trial to begin H1 2020 scancell can now afford to do it

August-GlycaCell commercial deal with a pharma

September- Modi2 manufacturing begins trial to start H1 2020 in 3 further new targets

October SCIB2 combo trial begins

November- new moditopes announced... plans to do moditope combo trials

December- month off everyone excited about coming year of data lots of interest and coverage in scancell a company now with an mcap stable around £500 million....scancell take on 2 new staff

The end lol ... oh and as for Brexit a peoples vote and 60% vote to remain...

July-

Fourteen are you saying your research is more detailed than what the BOD have chosen to RNS. Why wouldn"t you disagree with others, stating facts that support you?

Ray, it still doesn"t read as if there is a delay, as i read and you wrote CT H1 2019. Won"t they need funding for that if it still stands? Interesting.................

Rec too, you now have 14 recs!!

Ray/inanaco, thanks. It just reminded me as i was looking for any RNS that had specifically mentioned GC??

Best we forget histories or perceived ones.

Inanaco, no I wasn"t aware of it, and looked through a few RNSs to see whether any delay had been mentioned, and couldn"t find it. Now i understand why Knowlesi suggessted we are becoming known for delays, which i argued was down to SCIB 1 trial.

When did we hear that? Thanks

Many thanks for your post. Still trying to find out current situation with MOD1 /AMPLIVANT vaccine, should be completed now and ready as per Scancell for H1 2019 trials.

Considering very near term news for GC, SCIB1 IND and MOD1 H1 2019, we are looking very weak in the market IMHO?

From 16.22 at 8.50, not the greatest start to a New Year, lol.

Night.

Our posts crossed crumbs, just my opinion buti don"t think in our lifetimes they wil find a cure, but as per your 2nd paragraph that will be an almighty step forward in finding it.

Thanks Ivy, an interesting article from your link.

https://scienceblog.cancerresearchuk.org/2018/05/28/learning-from-a-cancers-past-could-predict-its-future/

What i do know is just a few weeks ago they can now predict growth by volume in a 12 month period of time. One for the techies.............."How can they predict mutations?"

Just reading various articles on scientific breakthroughs, the speed at which they are making progress is astonishing. Just keeping up with it must be very challenging, for all companies, let alone a small biotech like Scancell.

Ivy did you see my post re MOD1 conjugate and plans to be in trials H1 2019? Was that subject brought up at the recent AGM?